In the last trading session, 4.46 million FibroGen Inc (NASDAQ:FGEN) shares changed hands as the company’s beta touched 0.75. With the company’s per share price at $0.58 changed hands at -$0.13 or -17.81% during last session, the market valuation stood at $58.46M. FGEN’s last price was a discount, traded about -382.76% off its 52-week high of $2.80. The share price had its 52-week low at $0.18, which suggests the last value was 68.97% up since then.
Analysts gave the FibroGen Inc (FGEN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FGEN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. FibroGen Inc’s EPS for the current quarter is expected to be -0.2.
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN was in red as seen at the end of in last trading. With action 4.63%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 9.58%, with the 5-day performance at 4.63% in the green. However, in the 30-day time frame, FibroGen Inc (NASDAQ:FGEN) is 14.62% up.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 97.93% from its current market value. According to analyst projections, FGEN’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -4727.59% plunge from its current level, while the stock would need to soar -4727.59% for it to hit the projected low.
FibroGen Inc (FGEN) estimates and forecasts
Year-over-year growth is forecast to reach 20.37% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 24.91M. The company’s revenue for the corresponding quarters a year ago was 27.14M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -8.21%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.23%. The 2025 estimates are for FibroGen Inc earnings to increase by 72.60%, but the outlook for the next 5-year period is at 49.32% per year.
FGEN Dividends
FibroGen Inc is expected to release its next quarterly earnings report in March.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 8.9508% or 8.94 million shares worth $7.97 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Horizon Fund-Capital Opportunity Fund and Vanguard Total Stock Market Index Fund . With 3.98 shares estimated at $2.31 million under it, the former controlled 3.95% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.89% of the shares, roughly 2.92 shares worth around $1.69 million.
